Schantl Pharma Service

What Schantl Pharma Service does

Schantl Pharma Service GmbH is a privately held Contract Research Organization (CRO) founded in 1995 by Peter Schantl, specializing in clinical trial monitoring with a focus on oncology, particularly gynecological oncology. The company provides Phase I-IV monitoring services including on-site visits, report preparation, site personnel training, investigator meeting participation, and Lead CRA responsibilities. Complementary offerings include the "Flying Dokumentar" on-site documentation support module plus modern methodologies such as Risk-Based Monitoring and Remote Monitoring. The company operates a nationwide network of Clinical Research Associates (CRAs) distributed across multiple German cities (Griesheim, Kalletal, Köln, Nürnberg, Kißlegg, Quickborn) and extends coverage to Austria and Switzerland. The company is headquartered in Düsseldorf at Erasmusstr. 26 following a relocation from Wiesbaden in April 2019.

The business model is B2B professional services, generating revenue through contract-based engagements with pharmaceutical companies, universities, and research institutions. Customer segmentation spans three verticals: pharmaceutical companies (primary), universities and research institutions, and hospitals/medical centers. Notable past enterprise clients include Boehringer Ingelheim, Novartis, Bristol-Myers Squibb, AstraZeneca, Roche, GlaxoSmithKline, Lilly, and Amgen, while current clients include AGO Research GmbH, KKS Marburg, ZKS Hanover, and Leiden University Medical Center. The company has completed approximately 40 studies spanning ovarian cancer, endometrial cancer, cervical cancer, COPD, CML, psoriasis, Marginal Zone Lymphoma (MZL), and Progressive Multifocal Leukoencephalopathy (PML). Go-to-market is relationship-based enterprise field sales with no disclosed marketing infrastructure. Since April 2019 the company has been under the ownership and management of Iqbal Hügel (Inhaber & Geschäftsführer). The organization has 1-10 employees and operates without disclosed proprietary technology platforms, patents, certifications, or external funding.

Name

Schantl Pharma Service

Legal name

Schantl Pharma Service GmbH

Website

https://schantl-pharma-service.de

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

Schantl Pharma Service GmbH is a German boutique CRO founded in 1995 that provides Phase I-IV clinical trial monitoring services across Germany, Austria, and Switzerland, with a specialized focus on oncology, particularly gynecological oncology.

Ownership category

akta.pro rank

Headquarters

HQ city

Düsseldorf

HQ country

Germany

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Clinical Trial Monitoring Services: Contract research organization providing professional monitoring services for clinical trials. Revenue generated through service contracts with pharmaceutical companies, research institutions, and hospitals. Services include on-site monitoring, project management, and documentation support for Phase I-IV clinical studies.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Schantl Pharma Service GmbH is a Contract Research Organization (CRO) that provides clinical trial monitoring services for Phase I-IV studies, with a specialization in oncology (ovarian, endometrial, cervical cancers) and additional therapeutic areas such as COPD and CML. The company delivers on-site monitoring visits, monitoring reports, site personnel training, investigator meeting participation, Lead CRA responsibilities, and dedicated documentation support, leveraging a nationwide German network of Clinical Research Associates (CRAs) and serving clients in Germany, Austria, and Switzerland.

Product overview

Schantl Pharma Service GmbH is a Contract Research Organization (CRO) providing a unified clinical trial monitoring service with specialized focus on oncology, particularly gynecological oncology. The core offering consists of comprehensive clinical trial monitoring services (Phase I-IV), supplemented by specialized documentation support through the Flying Dokumentar module. The company also employs modern monitoring methodologies including Risk-Based Monitoring and Remote Monitoring approaches. They operate a nationwide network of Clinical Research Associates (CRAs) across Germany, with services also extended to Austria and Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Monitoring Services Comprehensive monitoring and oversight of clinical trials (Phase I-IV) for pharmaceutical, academic, and hospital clients, with specialization in oncology trials (ovarian, endometrial, cervical cancers, plus COPD, CML, psoriasis, MZL, PML). Deliverables include monitoring visits, monitoring visit reports, site personnel training, investigator meeting participation, and Lead CRA responsibilities.
• Flying Dokumentar (On-Site Documentation Support) Specialized on-site documentation support service providing efficient data management directly at clinical trial study sites, complementing the core monitoring service.

Named customers14 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• AGO Research GmbHcoreStrategic or Co-development PartnerCollaboration partner for gynecological oncology clinical research. AGO Research GmbH specializes in ovarian and gynecological cancer research and works with Schantl Pharma Service for clinical trial monitoring.
• Coordination Center for Clinical Trials Marburg (KKS)coreStrategic or Co-development PartnerUniversity-based clinical trials coordination center in Marburg. Partnership for monitoring clinical trials conducted at university hospital settings.
• Invisio Clinical Studies Consulting GmbHminorStrategic or Co-development PartnerClinical studies consulting partnership for specialized consulting services in clinical research.
• Forschungsdock CRO GmbHminorStrategic or Co-development PartnerPartnership with Forschungsdock CRO for expanded contract research organization services and capabilities.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Forschungsdock CRO GmbH: German CRO partnered with Schantl on expanded contract research services. Operates in the same niche, serving pharma and academic sponsors with similar clinical study support capabilities.
• Dr. Notghi Contract Research GmbH: Independent German CRO offering specialized contract research and clinical trial support. Already listed as a partnership/peer of Schantl and is directly comparable in scale, geography, and clinical monitoring focus.
• AGO Research GmbH: German gynecological oncology research organization and active client/partner of Schantl. Operates at the intersection of academic oncology trials and clinical monitoring services, making it a directly comparable peer.
• Invisio Clinical Studies Consulting GmbH: German clinical studies consulting partner of Schantl providing specialized consulting in clinical research. Comparable scale and regional focus on clinical trial enablement.

Regional players

• Nuvisan Pharma Services: Germany-headquartered CRO offering clinical and bioanalytical services across Europe. Comparable regional competitor with a deeper service portfolio but overlapping DACH customer base.

Broad incumbents

• Medpace Holdings: Mid-to-large global CRO with strong oncology franchise focused on mid-sized biopharma sponsors. Comparable in clinical trial execution but at vastly greater scale and geographic reach than Schantl.
• IQVIA Holdings: Largest global CRO with end-to-end clinical, data, and laboratory capabilities across all therapeutic areas including oncology. Sets the competitive ceiling for any clinical monitoring specialist.
• ICON plc: Global full-service CRO with broad therapeutic and geographic coverage, including oncology. Represents the scale of competitor that a small specialist like Schantl must either partner with or around.

Emerging players

• Clinipace Worldwide (now part of ICON): Mid-sized oncology-focused CRO serving small and mid-sized biopharma. Comparable therapeutic-area focus but broader geographic and functional footprint than Schantl.

Others

• Sponsor-based academic CTUs (KKS Marburg, ZKS Hannover): German university clinical trial units that are simultaneously Schantl's customers and potential competitor sources for in-house monitoring. Relevant ecosystem participants rather than direct substitutes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Schantl Pharma Service